Cognetivity Neurosciences Ltd.

As of October 31, 2023, Cognetivity Neurosciences Ltd. has 89.56M shares outstanding.

These figures are as of October 31, 2023. The price-to-sales ratio is 114.33, and the price-to-book ratio stands at -0.77.

These figures are as of October 31, 2023. The EV/Sales ratio of 145.11 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Cognetivity Neurosciences Ltd. trades at an EV/FCF ratio of 20.03, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of October 31, 2023, Cognetivity Neurosciences Ltd. maintains a current ratio of 0.02, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -18.01, indicating conservative leverage, while an interest coverage ratio of -0.94 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended October 31, 2023. Return on assets (ROA) is negative at -312.39, reflecting losses generated across the asset base.

As of the close on June 5, 2024, Cognetivity Neurosciences Ltd.'s stock has declined approximately 96.88% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.07.

Over the twelve months ended October 31, 2023, Cognetivity Neurosciences Ltd. posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -4,359.22 and net profit margin of -8,732.77 provide insight into operational efficiency.

These figures cover the twelve months ended October 31, 2023. Free cash flow yield is negative at -33.85: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.97, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Cognetivity Neurosciences Ltd. shareholders.

As of October 31, 2023, Cognetivity Neurosciences Ltd. has an Altman Z-Score of -242.33, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.